compare glp-1 drugs New for Weight Loss What Plan Sponsors Need to Know GLP-1 Drugs and Type 1

1 In a press release, Mark Cuban Cost Plus Drug Company CEO Alex Oshmyansky said, We are thrilled to collaborate with 9amHealth in our mission to make prescription drugs more affordable for consumers

Abstract Background There are concerns that glucagon-like peptide-1 receptor agonists (GLP1s) increase the risk of acute pancreatitis

Patients with high-deductible plans face $1,000 to $3,000 out-of-pocket costs before insurance coverage activates, delaying treatment by months

GLP-1 users saw a 44% reduction in hospitalizations due to stroke, heart attack and heart failure compared to the control group

While 8% of adults ages 65 and older say they have taken a GLP-1 medication for a chronic condition, just 1% say they have ever taken a GLP-1 drug to lose weight, which may reflect Medicares lack of coverage for prescription drugs used for weight loss

The first GLP-1 drug, exenatide, hit the market in 2005, and since then, companies have engineered more effective versions